MindMed to Participate at the Benzinga Global Small Cap Conference
NEW YORK, Dec. 2, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference to be held virtually on December 8-9, 2021.
Details on the conference can be found below.
Format: Corporate update and one-on-one investor meetings
Date: Thursday, December 9, 2021
Time: 4:00 p.m. ET
Webcast: Click Here
The webcast will also be accessible in the "Investors" section of MindMed's website. MindMed will maintain an archived replay of the webcast on its website for 30 days after the conference.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-at-the-benzinga-global-small-cap-conference-301436029.html
SOURCE Mind Medicine (MindMed) Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/02/c4619.html
DISCLAIMER:
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDARplus.ca for important risk disclosures. It’s your money and your responsibility.